| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 554.3 | 602.1 | 496.4 |
| Other income | 3.5 | 15.5 | 9.9 |
| Total income | 557.8 | 617.7 | 506.3 |
| Profit before exceptional items & tax | 98.0 | 138.9 | 80.7 |
| Exceptional items | 0.0 | 0.3 | 0.0 |
| Profit before tax | 98.0 | 139.2 | 80.7 |
| Net profit | 73.3 | 104.2 | 60.5 |
| Operating margin | 17.6% | 22.5% | 15.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +21.20% |
|---|---|
| Net profit, quarter on quarter | -29.70% |
| Revenue, year on year | +11.70% |
| Operating profit, year on year | +33.50% |
| Operating profit, quarter on quarter | -23.40% |
BSE results filing, NSE: SAILIFE. Figures extracted from the filing.
Sai Life Science Ltd: key numbers
- Share price
- ₹1,592.20
- Market cap
- ₹33,821 Cr
- Revenue (annual)
- ₹2,192 Cr
- Net profit (annual)
- ₹348.9 Cr
- P/E (TTM)
- 93.5×Sector 50.4×
- Promoter holding
- 34.53%-0.08% QoQ
- FII holding
- 19.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Life Science Ltd
All →Sai Life Science Employee Stock Options
Sai Life Sciences Limited has announced the allotment of equity shares under its ESOP scheme. This allotment increases the company's paid-up share capital.
Sai Life Science Employee Stock Options
Sai Life Sciences allotted 24,000 shares upon exercise of ESOP 2008 options at ₹188.90 per share. This issuance increases the company's paid-up equity share capital.
- Value
- ₹0.45 Cr
Sai Life Science Annual General Meeting
Sai Life Sciences summarised proceedings of its 27th AGM held 17 Sep 2026. Shareholders adopted FY25-26 financials and re-appointed MD Krishnamraju Kanumuri.
Sai Life Science Investor Presentation: Key Takeaways
Sai Life Sciences delivered strong Q1FY27 performance with revenue of ₹554 Cr, up 12% YoY, and PAT of ₹73 Cr, up 22% YoY, driven by growth in CRO and CDMO segments.
- Call
- Guides 20% growth
Sai Life Science Earnings Call: Key Takeaways
Sai Life Sciences reported robust FY26 performance with 29% revenue growth and 109% PAT growth, driven by deepening engagement with 19 of top 25 global pharma companies.
Sai Life Science Earnings Call: Key Takeaways
Sai Life Sciences delivered strong FY26 performance with 29% revenue growth and 56% EBITDA growth, driven by expansion in CDMO and CRO segments and improved operating leverage.